Ponazuril

Ponazuril is a triazine-based antiprotozoal drug, primarily used in veterinary medicine to treat Sarcocystis neurona (the causative agent of Equine Protozoal Myeloencephalitis, EPM) and other coccidial infections. It is the active metabolite of toltrazuril and works by disrupting protozoal mitochondrial electron transport and folate metabolism.

While ponazuril is not FDA-approved for human use, its mechanism of action and effects on parasitic infections have led to some speculative and experimental off-label applications, particularly in neurology and psychiatry.

Recent pharmacological research suggests that ponazuril might possess some nootropic properties of their own. A project aimed at identification of small molecules with a stimulatory effect on BDNF and NGF as a direction explored in signaling in search for novel treatment options for Alzheimer’s disease, depression, possibly other psychiatric conditions and disorders characterized by cognitive impairment, found ponazuril to be a positive allosteric modulator of Trk receptors. It demonstrated pro-cognitive effects in various preclinical in vivo models in mice. Cognitive enhancement was also seen in age-related decline in memory. Furthermore, studies in rodents suggest that ponazuril might display anti-depressant-like effects, as evidenced by the forced swim test model.

Toxoplasmosis, caused by the Toxoplasma gondii parasite, is estimated to infect 30-50% of the world’s population. Its prevalence varies significantly by region, and while in the United States it is believed to occur in around 11%, in some European countries it can affect as much as 90% people. It has been linked to psychiatric disorders (schizophrenia, bipolar disorder) and neurodegenerative conditions. Ponazuril’s ability to cross the blood-brain barrier (BBB) makes it a candidate for mitigating chronic Toxoplasma – related neuroinflammation. Anecdotal reports suggest improvements in brain fog, fatigue, and cognitive dysfunction in patients with suspected chronic parasitic infections.

Toxoplasma gondii alters dopamine and GABA pathways in the brain. Some neurodivergent individuals (particularly those with autism or ADHD) exhibit immune dysregulation, chronic infections, or elevated Toxoplasma antibodies. In such cases, antiprotozoals might help if an underlying infection exacerbates symptoms. By eliminating the parasite, ponazuril might restore normal neurotransmission in affected individuals. No direct studies exist, however, on ponazuril’s neuromodulatory effects beyond antiprotozoal action. Anecdotal reports suggest some children with autism and confirmed parasitic infections show behavioral improvements after antiprotozoal treatment, but controlled studies are lacking.

Ponazuril’s safety profile in humans is not well-established, though related drugs (i.e., nitazoxanide) are generally well-tolerated.

Benefits of taking ponazuril

• alleviated brain fog;

• decreased fatigue;

• improved cognitive function;

• better mood;

• anti-neuro inflammatory action;

• increased neuroplasticity;

• might improve hallucinations and cognitive clarity in treatment-resistant schizophrenia;

• prevents neuropsychiatric complications of persistent parasitic infection;

• potential aid in immune dysregulation;

• may restore healthy neurotransmission (i.e., if altered in Toxoplasmosis).

Side effects

(in veterinary use)

• diarrhea;

• nausea;

• elevated liver enzymes (rare).

Certain factors need to be taken into consideration if ponazuril were to be applied in humans. As a CYP3A4 substrate, potential drug interactions might occur (including, but not limited to, SSRIs and antifungals. It is of utmost importance to refrain from drinking grapefruit juice during treatment, preferably also for a few weeks following its use cessation.

Interestingly enough, ponazuril was shown to have an unexpectedly long half-life in humans. While in animals, it is rapidly absorbed, followed by a prolonged elimination, with terminal half-life in plasma between 0.3 to 7.9 days, the elimination half-life in plasma in humans was found to be significantly longer than predicted, with an average of 68 days.

Also, it is of paramount importance to be wary of immune reconstitution reactions (Herxheimer-like) that could potentially occur in the process of CNS parasite eradication. It is a sudden, typically transient reaction that may be mistaken for a drug allergy. Generally, it manifests within 24 hours of treatment as fever, chills, rigor, hypotension, headache, tachycardia, hyperventilation, vasodilation with flushing, myalgia (muscle pain), exacerbation of skin lesions and anxiety. It is not typically reported in protozoal infections, however, some studies suggest the reaction might be triggered by antifungal treatments for certain infections, potentially involving protozoa. Such reactions can be life-threatening for its potential to cause severe hypotension, and acute end-organ injury, eventually leading to multi-organ failure.

Dosage

Since no formal human trials exist, dosing is extrapolated from veterinary data.

Anecdotal reports from off-label use suggest 500–1500 mg/day (divided into 1–2 doses), most typically 5-10 mg/kg, with initial dose ranging from 200 to 500 mg/day, over a 4–12-week period.

Ponazuril is poorly water-soluble; in order to enhance its absorption it is advised to ingest it with fatty meals.